• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book Apps
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » How Effective Is Tramadol for Opioid Withdrawal?

How Effective Is Tramadol for Opioid Withdrawal?

September 1, 2017
Taylor Noriega, PharmD candidate (2018).
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Taylor Noriega, PharmD candidate (2018). Ms. Noriega has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Dunn K et al, JAMA Psychiatry 2017. doi:10.1001/jamapsychiatry.2017.1838. [Epub ahead of print]

Opioid withdrawal protocols often rely on a buprenorphine taper, but other medications are regularly used either in addition to or in the place of buprenorphine. In particular, tramadol ER, a mild opiate, may be effective and was recently studied at Johns Hopkins University School of Medicine.

A total of 103 participants with opioid dependence were enrolled in this study comparing tramadol ER (n = 36), buprenorphine (n = 31), and clonidine (n = 36) for opioid withdrawal. Overall, 88 of the subjects (85.4%) were male, 43 (41.7%) were white, and average age was 29 years. Past 30-day use of heroin was reported by 96 (93.2%) of the ­participants vs. 49 (47.5%) who reported using prescription opioids in that time period (some used both).

People in the study were randomized to three arms: tapering with tramadol (up to 600 mg/day), clonidine (up to 0.8 mg/day), or buprenorphine (up to 8 mg/day). Following the week-long taper, all participants were crossed over to placebo for a week, then were given a naloxone challenge to verify successful withdrawal.

The trial used several measures, including the Subjective Opiate Withdrawal Scale (SOWS) completed by participants, the Clinical Opiate Withdrawal Scale (COWS) completed by clinicians, pupil diameter, and concomitant medication use (mostly over-the-counter meds for GI symptoms, pain, and sleep).

Researchers found that tramadol ER was more effective than clonidine and comparable to buprenorphine in terms of patient retention and withdrawal symptom suppression during the 7-day detox period. Patients treated with clonidine and tramadol used more concomitant supportive medications during the taper than those on buprenorphine, though the number of meds used was low (0–2) across all three groups.

CATR’s Take
Based on this study, tramadol seems like an attractive option—you don’t need a buprenorphine waiver, and it may be more effective than clonidine. Considering it is an opioid agonist, it’s no surprise that tramadol helps alleviate withdrawal symptoms. But the doses of tramadol used were particularly high (usual dose in pain is 50–200 mg/day), whereas the doses of buprenorphine were relatively low (usual dose in detox is 8–16 mg/day). Still, if buprenorphine is not an option, then tramadol could be worth considering. Just be cautious of drug interactions, especially with serotonergic agents (increased seizure risk).
Addiction Treatment
KEYWORDS addiction pharmacology-tips research-update substance-abuse
    Taylor Noriega, PharmD candidate (2018).

    More from this author
    www.thecarlatreport.com
    Issue Date: September 1, 2017
    SUBSCRIBE NOW
    Table Of Contents
    Take The CME Post-Test for Detox, CATR, September/October 2017
    Cannabis Use Disorder Treatment
    Kratom: A Primer for Clinicians
    How Effective Is Tramadol for Opioid Withdrawal?
    Detox: An Overview
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2635946985.jpg
      General Psychiatry

      AI in Practice

      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.